Previous close | 9.50 |
Open | 9.48 |
Bid | 9.60 x 1000 |
Ask | 0.00 x 1100 |
Day's range | 9.18 - 9.73 |
52-week range | 9.18 - 21.05 |
Volume | |
Avg. volume | 560,380 |
Market cap | 605.884M |
Beta (5Y monthly) | 1.68 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.05 |
Earnings date | 04 Dec 2023 - 08 Dec 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.25 |
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 100% and 10.96%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (NASDAQ: CDMO) hasn't been a very lively investment in recent days. According to data compiled by S&P Global Market Intelligence, the specialty healthcare company's stock was down 17% week to date as of early Friday morning. Avid Bioservices, a contract developer and manufacturer of biologics, released its fiscal 2023 fourth-quarter results after market hours on Wednesday.
Shares of Avid Bioservices (NASDAQ: CDMO) were down more than 12% Thursday afternoon after falling as much as 17% earlier in the day. The drop came after the biologics contract development and manufacturing organization (CDMO) released fourth-quarter and full-year fiscal 2023 earnings. Avid's stock is down more than 2% so far this year.